In a breast cancer xenograft model, melatonin suppressed the expression of VEGFR-2, the most critical receptor of VEGF, to significantly reduce vascular density and angiogenesis [157], while in HUVECs, melatonin showed a dose-dependent inhibition of VEGFR-2 induced by VEGF [158]. Here, VEGFA is linked to breast carcinoma.